
In a multicenter study of 246 patients with BPH and prostates ≥80 mL, Rezūm and ThuLEP improved urinary symptoms and erectile function. ThuLEP showed greater symptom score reductions, but differences were not clinically meaningful. Rezūm preserved ejaculatory function better and had fewer severe complications. Rezūm may offer a less invasive, function-sparing option for select patients.
Like
Save
Share